Efficacy of Imatinib Dose Escalation in Patients With Chronic Myeloid Leukemia in Chronic Phase

BACKGROUND: Imatinib mesylate given orally at a daily dose of 400 mg is the standard of care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP). Treatment guidelines propose dose escalation based on clinical assessments of disease response. METHODS: Respons...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Kantarjian, Hagop M., Larson, Richard A., Guilhot, Francois, O’Brien, Stephen G., Mone, Manisha, Rudoltz, Marc, Krahnke, Tillmann, Cortes, Jorge, Druker, Brian J.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4445370/
https://ncbi.nlm.nih.gov/pubmed/19117345
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24066
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars